clinical trial · NCT06673043
Anifrolumab Real-world Treatment Outcomes in Systemic Lupus Erythematosus
AstraZeneca·—·recruiting·n = 100
Lupus Erythematosus, SystemicAnifrolumab
brief summary
The Polish multicentre observational (non-interventional) study aiming to collect data on the characteristic of patients with systemic lupus erythematosus and clinical outcomes of anifrolumab administered in the scope of routine clinical practice.
started
Feb 28, 2025
primary completion
Jun 30, 2028
completion
Jun 30, 2028
last updated
Apr 13, 2026
detailed description
This is multicenter, observational, cohort study designed to collect longitudinal data on the management and clinical outcomes of patients with SLE that received anifrolumab in the scope of routine clinical practice within the frames of National Drug Program (NDP) for up to 30 months (\~ 6 months baseline and \~24 months follow-up date).
official title
Anifrolumab Real-world Treatment Outcomes in Polish Patients With Systemic Lupus Erythematosus (SLE). Multicenter, Non-interventional Study
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol